4-Substituted Bicyclohexane mGlu2 Agonists for Psychiatric Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical practices lack effective mGlu2 agonists with appropriate drug-like properties to treat excessive glutamatergic tone-related disorders, such as schizophrenia, bipolar disorder, depression, and generalized anxiety disorder.
Innovation Solution
Development of novel 4-substituted bicyclo[3.1.0]hexane compounds, including specific prodrugs and their salts and solvates, which act as potent mGlu2 agonists, enhancing bioavailability for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional mGlu2 agonists are used, then receptor activation is achieved, but bioavailability and drug-like properties are insufficient for clinical use
Solution Approach 1:
The patent modifies the chemical structure of mGlu2 agonists by introducing specific substituents at the 4-position of the bicyclo[3.1.0]hexane core (such as aryl, heteroaryl, and alkyl groups) to optimize pharmacokinetic properties including bioavailability while maintaining potent receptor activation. This structural parameter change resolves the contradiction between achieving reliable bioavailability and maintaining clinical efficacy.
2Productivity
If existing mGlu2 agonist structures are used, then some receptor activity is achieved, but potent and efficacious treatment of psychiatric disorders is not realized
Solution Approach 1:
The patent introduces specific local substitutions at the 4-position of the bicyclo[3.1.0]hexane core with carefully selected functional groups (aryl, heteroaryl, alkyl) to enhance both therapeutic efficacy and drug-like properties. This localized structural modification allows the molecule to achieve potent mGlu2 activation while simultaneously improving pharmacokinetic reliability for clinical treatment of psychiatric disorders.
3Adaptability or versatility
If mGlu2/3 agonists are used, then antipsychotic properties are achieved, but the specific contribution of mGlu2 versus mGlu3 activation is not optimized
Solution Approach 1:
Rather than designing agonists that non-selectively activate both mGlu2 and mGlu3 receptors, the patent inverts the approach by developing compounds with preferential mGlu2 selectivity through specific 4-substitution patterns. This selective mGlu2 activation maintains antipsychotic efficacy while reducing off-target effects, thereby optimizing the adaptability and versatility of the therapeutic agent.
Data Source
AI summary
The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder. The novel agonists are represented by the formula.